CA2695452A1 - Hdac inhibitors - Google Patents

Hdac inhibitors Download PDF

Info

Publication number
CA2695452A1
CA2695452A1 CA2695452A CA2695452A CA2695452A1 CA 2695452 A1 CA2695452 A1 CA 2695452A1 CA 2695452 A CA2695452 A CA 2695452A CA 2695452 A CA2695452 A CA 2695452A CA 2695452 A1 CA2695452 A1 CA 2695452A1
Authority
CA
Canada
Prior art keywords
dihydro
pyrrolo
compound
amino
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2695452A
Other languages
English (en)
French (fr)
Inventor
Mark A. Ashwell
Manish Tandon
Nivedita D. Namdev
Jean Marc Lapierre
Yanbin Liu
Hui Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2695452A1 publication Critical patent/CA2695452A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2695452A 2007-08-21 2008-08-21 Hdac inhibitors Abandoned CA2695452A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96558407P 2007-08-21 2007-08-21
US60/965,584 2007-08-21
PCT/US2008/073873 WO2009026446A2 (en) 2007-08-21 2008-08-21 Hdac inhibitors

Publications (1)

Publication Number Publication Date
CA2695452A1 true CA2695452A1 (en) 2009-02-26

Family

ID=39828970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2695452A Abandoned CA2695452A1 (en) 2007-08-21 2008-08-21 Hdac inhibitors

Country Status (6)

Country Link
US (1) US20100261710A1 (enExample)
EP (1) EP2190845A2 (enExample)
JP (1) JP2010536876A (enExample)
CN (1) CN101835778A (enExample)
CA (1) CA2695452A1 (enExample)
WO (1) WO2009026446A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009286604B2 (en) 2008-08-29 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Novel urea and thiourea derivatives
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8546588B2 (en) 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2013041407A1 (en) * 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
CN103974956B (zh) * 2011-11-29 2016-07-06 南京奥昭生物科技有限公司 作为hdac6抑制剂和用作抗肿瘤剂的杂环酰胺化合物
WO2013154870A1 (en) 2012-04-10 2013-10-17 Annji Pharmaceutical Co., Ltd. Histone deacetylases (hdacs) inhibitors
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
ES2697775T3 (es) * 2013-04-29 2019-01-28 Chong Kun Dang Pharmaceutical Corp Compuestos novedosos para inhibidores selectivos de histona desacetilasa y composición farmacéutica que comprende los mismos
KR102576274B1 (ko) 2017-05-16 2023-09-07 안지 파마슈티컬 코퍼레이션 리미티드 히스톤 데아세틸라제(hdac) 저해제
CN113121527B (zh) * 2019-12-31 2024-09-06 上海辉启生物医药科技有限公司 三环类化合物及其用途
JP2023530788A (ja) 2020-06-08 2023-07-19 アンジー ファーマシューティカル カンパニー リミテッド 選択的ｈｄａｃ６阻害剤として有用なキナゾリン誘導体
CN119143740B (zh) * 2024-08-15 2025-11-14 杭州科兴生物化工有限公司 一种苯并噻吩类衍生物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083005A1 (en) * 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
AR035417A1 (es) * 2001-01-27 2004-05-26 Hoffmann La Roche Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
CA2531661C (en) * 2003-07-07 2013-03-12 Georgetown University Histone deacetylase inhibitors and methods of use thereof
ITFI20050041A1 (it) * 2005-03-15 2006-09-16 Menarini Internat Operations Luxembourg Sa Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono

Also Published As

Publication number Publication date
WO2009026446A3 (en) 2009-09-11
EP2190845A2 (en) 2010-06-02
US20100261710A1 (en) 2010-10-14
JP2010536876A (ja) 2010-12-02
WO2009026446A8 (en) 2010-04-29
CN101835778A (zh) 2010-09-15
WO2009026446A2 (en) 2009-02-26
WO2009026446A9 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
CA2695452A1 (en) Hdac inhibitors
Ahmed et al. Design, synthesis, molecular docking of new lipophilic acetamide derivatives affording potential anticancer and antimicrobial agents
JP4674231B2 (ja) ２量体小分子アポトーシス増強剤
WO2021113595A1 (en) Phosphorus derivatives as kras inhibitors
JP7175888B2 (ja) 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体
CN103880841B (zh) 含有β-咔啉-3-酰亚肼基的HDAC抑制剂及其制备方法和用途
PL212494B1 (pl) Nowe zwiazki chemiczne, kompozycje zawierajace nowe zwiazki chemiczne i zastosowanie nowych zwiazków chemicznych
JP7068297B2 (ja) フェニル及びピリジニルヒドロキサム酸
AU610739B2 (en) Thiazolo (5,4-b)azepine compounds
CN105254635A (zh) 一类咪唑并吡嗪类化合物及其药物组合物和用途
AU2020255702B2 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
CN116354901B (zh) 一种噻唑烷二酮类化合物及其制备方法和应用
Li et al. Novel pyrrolo [2, 1-c][1, 4] benzodiazepine-3, 11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo
WO2021115188A1 (zh) 一种组蛋白去乙酰化酶、蛋白酶体双靶点抑制剂及其制备方法和应用
JP2022550489A (ja) スルホ置換ビアリール化合物又はその塩並びにその調製方法及び使用
JP4792128B2 (ja) 癌に対するｈｓｐ９０阻害剤としての５−（２−ヒドロキシフェニル）テトラゾール
JP2022502497A (ja) Ｈｄａｃ１、２の阻害剤
CN108794474B (zh) 具有多靶点抗肿瘤活性的吴茱萸碱衍生物及其制备方法和应用
Yang et al. Design, synthesis, and structure–activity relationships of 1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid derivatives as inhibitors of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint pathway
KR101734868B1 (ko) 벤조푸라논 화합물 및 그것을 포함하는 의약 조성물
CA2973484A1 (en) Furoquinolinediones as inhibitors of tdp2
JPH08269008A (ja) ディスタマイシン類似構造をもつ化合物と、それを含む抗癌剤
CN112079836B (zh) 三唑并嘧啶类化合物及其盐、组合物和应用
WO2025064325A1 (en) Gpr35 modulators
Shah et al. Design, synthesis and evaluation of antimicrobial and anticancer activity of novel 3-aminomethyl pyridin derivatives

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130821

FZDE Discontinued

Effective date: 20130821